| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-737 | |
| Phytochemical name or plant extracts | Berberine | |
| PMID | 27322681 | |
| Literature evidence | Our study reveals the mechanism underlying berberine's inhibition of cell proliferation and migration in basal-like breast cancer, highlighting the use of berberine as a potential adjuvant therapeutic agent. | |
| IUPAC name | 16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene | |
| Phytochemicals’ class or type of plant extracts | Alkaloid | |
| Source of phytochemicals or plant Extracts | Coptis chinensis | |
| Geographical availability | China North-Central, China South-Central, China Southeast, Vietnam | |
| Plant parts | NA | |
| Other cancers | Breast cancer, Colon cancer, Liver cancer | |
| Target gene or protein | EGFR, GPER1, ABCG2, CYP1A1, HMGB1, ABCG2, IL-1β, IL-6,TNF-α, NF-κB, Bax, Bcl-2, EGFR, AKT, P38, ERK1/2 | |
| Gene or Protein evidence | The activity of EGFR was affected by berberine, however, berberine dramatically reduced EGFR phosphorylation, berberine treatment was associated with a decrease in expression of ABCG2 relative to untreated controls, Berberine Activates Aryl Hydrocarbon Receptor but Suppresses CYP1A1 Induction through miR-21-3p Stimulation in MCF-7 Breast Cancer Cells. These results indicate that the growth inhibitory effects of berberine treatment on MCF-7 cells may be partly via effects on SP and ABCG2 expression. The increased levels of lipid peroxide (malonaldehyde), pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α), enzymatic antioxidants (SOD and CAT), non-enzymatic antioxidants (GSH and vitamin C) and transcription factor NF-κB were decreased significantly by administration of berberine. Enhancement of Bax content detected by ELISA and upregulation of Bax mRNA expression, down-regulation of Bcl-2 expression and increase of anion superoxide production confirmed induction of apoptosis via intrinsic apoptotic pathway. The activity of EGFR, AKT, P38, and ERK1/2 were affected by berberine; however, berberine dramatically reduced EGFR and AKT phosphorylation. | |
| Target pathways | Mitochondria and caspase dependent apoptotic pathway Triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress NLRP3 Inflammasome pathway | |
| IC50 | 50 μM against MDA-MB-231 15 μM against MCF-7 | |
| Potency | The cells were then treated with different concentrations (0, 1 nM, 10 nM, 100 nM, 1 μM, 10 μM, 20 μM, 50 μM, 100 μM and 500 μM) of berberine for 24 h. | |
| Cell line/ mice model | Cytotoxic effect on MCF-7 cells, inhibitory effect on the growth of breast, liver and colon cancer cell lines (MCF-7, HepG2 and CACO-2, respectively). MDA-MB-231, the human ductal breast epithelial tumor cell line (T47D cell line) | |
| Additional information | Berberine as well as lovastatin, an inhibitor of the mevalonate pathway, exerted dose-dependent cytostatic/cytotoxic effects against human breast cancer cells (MDA-MB231), Berberine suppresses the TPA-induced MMP-1 and MMP-9 expressions through the inhibition of PKC-α in breast cancer cells, the growth inhibitory effects of berberine treatment on MCF-7 cells may be partly via effects on SP and ABCG2 expression. Combined treatment of Berberine and theophylline reduced extracellular level of HMGB1 and down regulated HMGB1 and MMP-9 mRNA expression. | |
| PubChem ID | 2353 | |
| Additional PMIDs | 17089049 18951337 19800775 20691179 24973693 27322681 28544934 29143794 30119256 30343043 31412862 32258115 32707493 34643248 22522123 29805448 34981469 30957305 31338966 26019795 33100936 29061795 19052522 21699261 22381172 22950834 22895634 24335179 24289631 27081456 27432642 28533175 33621894 34768896 22081376 24696391 19800775 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:710313-1 | |
| Safety | NA |